Contact
searchSearch
HMP Global
Login

Multiple Myeloma

Multiple Myeloma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Binod Dhakal, MD
Videos
Allogeneic BCMA CAR T-Cell Therapy Demonstrates Durable Activity and Manageable Safety in Relapsed or Refractory Multiple Myeloma
06/23/2026
Binod Dhakal, MD
Binod Dhakal, MD, discusses results from the phase 1 CaMMouflage trial supporting the use of the allogeneic BCMA-directed CAR T-cell therapy CB-011 as a potentially scalable off-the-shelf treatment option for patients with relapsed or...
Binod Dhakal, MD, discusses results from the phase 1 CaMMouflage trial supporting the use of the allogeneic BCMA-directed CAR T-cell therapy CB-011 as a potentially scalable off-the-shelf treatment option for patients with relapsed or...
Binod Dhakal, MD, discusses...
06/23/2026
Oncology
Saurabh Chhabra, MD
Videos
Etentamig Demonstrates Durable Activity Following Prior BCMA Therapy in Multiple Myeloma
06/23/2026
Saurabh Chhabra, MD
Saurabh Chhabra, MD, discusses results from the phase 1b MOVISO trial showing that the next-generation BCMA×CD3 bispecific antibody etentamig produced durable responses and manageable toxicity in heavily pretreated patients with relapsed or...
Saurabh Chhabra, MD, discusses results from the phase 1b MOVISO trial showing that the next-generation BCMA×CD3 bispecific antibody etentamig produced durable responses and manageable toxicity in heavily pretreated patients with relapsed or...
Saurabh Chhabra, MD, discusses...
06/23/2026
Oncology
Roberto Mina, MD
Videos
MajesTEC-9 Establishes Teclistamab as a New Standard in Early Relapsed or Refractory Multiple Myeloma
06/23/2026
Roberto Mina, MD
Roberto Mina, MD, discusses results from the phase 3 MajesTEC-9 trial showing that teclistamab significantly improved progression-free survival, overall survival, complete response rates, and MRD negativity compared with standard-of-care...
Roberto Mina, MD, discusses results from the phase 3 MajesTEC-9 trial showing that teclistamab significantly improved progression-free survival, overall survival, complete response rates, and MRD negativity compared with standard-of-care...
Roberto Mina, MD, discusses...
06/23/2026
Oncology
Peter Frosberg, MD
Videos
Feasibility of Community-Based Outpatient Bispecific Therapy in Multiple Myeloma
06/19/2026
Peter Forsberg, MD
Peter Forsberg, MD, discusses results from the phase 2 OPTEC trial showing that prophylactic tocilizumab reduced cytokine release syndrome rates to 5% with teclistamab and 14% with talquetamab while maintaining strong efficacy and enabling...
Peter Forsberg, MD, discusses results from the phase 2 OPTEC trial showing that prophylactic tocilizumab reduced cytokine release syndrome rates to 5% with teclistamab and 14% with talquetamab while maintaining strong efficacy and enabling...
Peter Forsberg, MD, discusses...
06/19/2026
Oncology
Sikander Ailawadhi, MD
Videos
Isatuximab Retreatment After Prior Anti-CD38 Therapy in Relapsed or Refractory Multiple Myeloma
06/19/2026
Sikander Ailawadhi, MD
Sikander Ailawadhi, MD, discusses post hoc analysis results from the phase 3 IRAKLIA trial showing that isatuximab plus pomalidomide and dexamethasone retained meaningful clinical activity in patients with relapsed or refractory multiple...
Sikander Ailawadhi, MD, discusses post hoc analysis results from the phase 3 IRAKLIA trial showing that isatuximab plus pomalidomide and dexamethasone retained meaningful clinical activity in patients with relapsed or refractory multiple...
Sikander Ailawadhi, MD,...
06/19/2026
Oncology
Enrique Ocio, MD, PhD
Videos
DREAMM-9 Final Analysis Shows Strong Efficacy With Belantamab Mafodotin Plus VRd in Newly Diagnosed Multiple Myeloma
06/16/2026
Enrique Ocio, MD, PhD
Enrique Ocio, MD, PhD, discusses final results from the DREAMM-9 trial which showed that dose-adapted belantamab mafodotin plus bortezomib, lenalidomide, and dexamethasone achieved high response rates, deep MRD-negative remissions, and...
Enrique Ocio, MD, PhD, discusses final results from the DREAMM-9 trial which showed that dose-adapted belantamab mafodotin plus bortezomib, lenalidomide, and dexamethasone achieved high response rates, deep MRD-negative remissions, and...
Enrique Ocio, MD, PhD, discusses...
06/16/2026
Oncology
Roberto Mina, MD
Videos
Teclistamab Monotherapy Improves Outcomes in Patients With Relapsed or Refractory Multiple Myeloma
06/16/2026
Roberto Mina, MD
Roberto Mina, MD, discusses results from the phase 3 MajesTEC-9 trial evaluating teclistamab monotherapy in patients with relapsed or refractory multiple myeloma.
Roberto Mina, MD, discusses results from the phase 3 MajesTEC-9 trial evaluating teclistamab monotherapy in patients with relapsed or refractory multiple myeloma.
Roberto Mina, MD, discusses...
06/16/2026
Oncology
Omar Nadeem, MD
Videos
Teclistamab Achieves Deep MRD-Negative Responses in High-Risk Smoldering Myeloma
06/15/2026
Omar Nadeem, MD
Omar Nadeem, MD, discusses results from the phase 2 ImmunoPRISM trial evaluating teclistamab in patients with high-risk smoldering multiple myeloma.
Omar Nadeem, MD, discusses results from the phase 2 ImmunoPRISM trial evaluating teclistamab in patients with high-risk smoldering multiple myeloma.
Omar Nadeem, MD, discusses...
06/15/2026
Oncology
Luca Bertamini, MD
Videos
Genomic Risk Stratification in Newly Diagnosed Multiple Myeloma
05/29/2026
Luca Bertamini, MD
Luca Bertamini, MD, discusses the application of the newly established IMS/IMWG genomic risk classification in newly diagnosed patients with multiple myeloma.
Luca Bertamini, MD, discusses the application of the newly established IMS/IMWG genomic risk classification in newly diagnosed patients with multiple myeloma.
Luca Bertamini, MD, discusses...
05/29/2026
Oncology
Mattia D'Agostino, MD
Videos
Sustained MRD Negativity Predicts Long-Term Outcomes in Multiple Myeloma
05/29/2026
Mattia D'Agostino, MD, discusses long-term MRD analyses from the phase 2 FORTE trial evaluating different induction, consolidation, and maintenance strategies in newly diagnosed patients with multiple myeloma.
Mattia D'Agostino, MD, discusses long-term MRD analyses from the phase 2 FORTE trial evaluating different induction, consolidation, and maintenance strategies in newly diagnosed patients with multiple myeloma.
Mattia D'Agostino, MD, discusses...
05/29/2026
Oncology

Section Editor

Shaji Kumar, MD
Mayo Clinic, Rochester, Minnesota

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use